Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.

BMC Med · 2017 · PMC5558721 · PMID 28810856

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

PFS showed a trend toward improvement in the patients treated with the combination, with a HR of 0.559, albeit not statistically significant at the time of analysis.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.